Your Messages Inbox
Most Viewed Abstracts
1. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 2. Omega-3 fatty acids for bipolar disorder 3. Is folic acid good for everyone 4. ACS Releases Guidelines for HPV Vaccination 5. Vitamin D - A review Free full text
Your Article Summary
See Latest ArticlesDuloxetine in the treatment of irritable bowel syndrome: an open-label pilot study
Human Psychopharmacology: Clinical and Experimental, 07/01/09
Brennan BP et al. - Open-label study, duloxetine appeared to be effective for many features of IBS, but its adverse effects, most notably constipation, limited its use. Since our study excluded individuals with concurrent major depression, it appears that duloxetine may benefit IBS independently of its antidepressant effects. These encouraging but preliminary open-label findings support further investigation of duloxetine treatment in placebo-controlled trials of IBS.
Methods- Open-label 12-week trial of duloxetine 60 mg daily in 15 patients with IBS without concurrent major depressive disorder.
- The primary outcome measure was average abdominal pain.
- Secondary measures included IBS symptoms, Clinical Global Impression-Severity, Hamilton Anxiety Rating Scale, IBS Quality-of-Life Scale, and Sheehan Disability Scale.
- Analyzed changes using random regression and one-sample t-tests.
- Fourteen patients completed at least one post-baseline evaluation; eight completed the study.
- Duloxetine was associated with significant improvement (p < 0.05) in pain, severity of illness, quality of life, loose stool, work and family disability, and anxiety.
- However, duloxetine did not improve hard stool.
- Found no evidence of serious duloxetine toxicity, seven participants withdrew over the course of the study because of adverse drug events.
Related Articles
The short- and long-term effect of duloxetine on painful physical symptoms in patients with generalized anxiety disorder: Results from three clinical trials
Journal of Anxiety Disorders, 11/13/09
Relevance Score: 66%
Fibromyalgia: The diagnosis and pharmacologic treatment
European Journal of Pain, 11/12/09
Relevance Score: 64%
Milnacipran, a serotonin and norepinephrine reuptake inhibitor: a novel treatment for fibromyalgia
International Journal of Clinical Rheumatology, 10/19/09
Relevance Score: 64%
Review: differences in efficacy and acceptability exist for 12 new-generation antidepressants for major depression
Evidence-Based Medicine, 10/26/09
Relevance Score: 63%
Tinnitus in postherpetic neuralgia
The Journal of Headache and Pain, 10/26/09
Relevance Score: 62%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Divalproex Sodium-Induced Eosinophilic Pleural Effusion
American Journal of Therapeutics, 12/04/09
Lithium and thyroid
Best Practice & Research Clinical Endocrinology & Metabolism, 12/04/09
Long-term experience with etanercept in psoriatic arthritis patients: A 3-year observational study
Journal of Dermatological Treatment , 12/04/09
Today in Gastroenterology...keeping you current
Receive free subspecialty "5-minute updates" via email
Is There Still a Role for Peripheral Parenteral Nutrition?
Nutrition in Clinical Practice, 12/04/09
Patients' views of medical positioning for proctologic examination
Clinical and Experimental Gastroenterology, 12/04/09
Review article: sleep-related gastro-oesophageal reflux as a distinct clinical entity
Alimentary Pharmacology and Therapeutics, 12/04/09
Sponsor
Article Search
Sponsor
Sponsor